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Background: Patient registries have great potential for providing data that describe disease burden, treatments,
and outcomes; which can be used to improve patient care. Many renal registries exist, but a central repository of
their scope, quality, and accessibility is lacking. The objective of this study was to identify and assess worldwide
renal registries reporting on renal replacement therapy and compile a list of those most suitable for use by a broad
range of researchers.
Methods: Renal registries were identified through a systematic literature review and internet research. Inclusion
criteria included information on dialysis use (yes/no), patient counts ≥300, and evidence of activity between June
2007 and June 2012. Public availability of information on dialysis modality, outcomes, and patient characteristics as
well as accessibility of patient-level data for external research were evaluated.
Results: Of 144 identified renal registries, 48 met inclusion criteria, 23 of which were from Europe. Public accessibility
to annual reports, publications, or basic data was good for 17 registries and moderate for 22. Patient-level data were
available to external researchers either directly or through application and review (which may include usage fees) for
13 of the 48 registries, and were inaccessible or accessibility was unknown for 25.
Conclusions: The lack of available data, particularly in emerging economies, leaves information gaps about health care
and outcomes for patients with renal disease. Effective multistakeholder collaborations could help to develop renal
registries where they are absent, or enhance data collection and dissemination for currently existing registries to improve
patient care.
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Peritoneal dialysisBackground
Patient registries provide an organized and standardized
method to systematically collect observational data about
specific groups of patients managed in routine clinical
practice for a predetermined objective [1]. Registry data
can help describe the natural history, epidemiology, and
burden of a disease; and capture treatment site, regional,
or national variations in treatment and outcomes to help
evaluate safety, quality, and value of patient care [2]. Ul-
timately, data collected by patient registries may help
researchers develop hypotheses about disease mecha-
nisms or treatment approaches and inform health care
policy thereby potentially improving quality. However,* Correspondence: xiaoqing_liu@baxter.com
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unless otherwise stated.establishing a registry is a major undertaking, requiring
sizeable resource investment from payers, health care
providers (HCPs), and technical/administrative staff to
initiate and maintain registry operation [1]. For coun-
tries with a limited pool of HCPs and resources, these
obstacles may prohibit patient registry initiation.
End-stage renal disease (ESRD) and its current stand-
ard of care, renal replacement therapy (RRT; which in-
cludes dialysis and/or kidney transplantation) result in
substantial economic and societal costs. Despite affecting
up to 0.03% of the total population in developed coun-
tries, ESRD consumes up to 3% of annual healthcare
budgets in many countries [3], and even more in the
United States (US). In 2011, US Medicare-related total
ESRD expenditures were $34.4 billion, accounting for
7.2% of the total Medicare budget while serving onlys is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Medicare costs per patient using hemodialysis (HD) or
peritoneal dialysis (PD) were approximately $88,000 and
$72,000, respectively [4]. Global incidence rates for RRT
range from 12 to 455 (median 130) per million population
[5], with an increase of 6% to 7% annually, markedly out-
pacing the annual population growth rate of 1.2% [6]. The
incidence of RRT varies considerably between countries
due to factors like gross domestic product (GDP) per
capita, percentage of GDP spent on health care, dialysis
reimbursement rate, and the private for-profit share of
dialysis provision [5]. These may contribute to faster
growth rates in underdeveloped countries (in line with
economic development) compared with wealthier coun-
tries where increases are driven more by ESRD incidence
than access to RRT.
In the field of ESRD care, registries—some with long
standing histories—have been widely established to collect
data on patients undergoing RRT. Data from these regis-
tries can provide useful information to assess the effective-
ness of treatment options, identify patients who could
benefit from an existing or new treatment, and drive im-
provements in health care quality [7]. Moreover, registry
data have revealed a variability in incidence, prevalence,
and treatment modalities across the world [5], some of
which may be explained by patient demand, and others by
economic and provider-driven demand.
The global distribution, availability, and quality of renal
registries are unclear, and the burden of ESRD in many
low- and middle-income countries is not fully understood,
due to a lack of national registries [8]. Therefore, there is a
need to better understand the global distribution of ESRD
registries, the type of data recorded and available, and the
applicability of such data for improvements in clinical and
policy decisions. An integrated, central repository of global
renal registry data could help illustrate trends and out-
comes from RRT, and ultimately lead to improved quality
and consistency in care within a particular country, but
also identify best practice across countries.
The objective of this research was to systematically iden-
tify and compile information about existing renal registries
reporting RRT across the world, including an examination
of their data elements and an evaluation of data accessibil-
ity. Accessibility was defined as availability of aggregate
data, publication of periodic reports and/or literature in
peer-reviewed journals, and accessibility to external re-
searchers of anonymized patient-level data to investigate
parameters like epidemiology, treatment patterns, and
health outcomes for patients with ESRD. Additional objec-
tives were as follows: to provide a resource that describes
high-quality, accessible renal registries; identify regions
with a need to commence or improve data collection; and
increase availability of information to educate the public or
inform clinical research by external investigators.Methods
Registries of patients with ESRD receiving dialysis were
initially identified through a systematic literature review
using Cochrane Renal Group standard search strings [9]
to identify publications on renal registries through publicly
available resources such as Medline/PubMed, Embase,
the Cochrane Library, and the Centre for Reviews and
Dissemination databases (Additional file 1). All human
studies identified were included without date or lan-
guage restrictions. Internet searches for renal registry
websites were also performed. If the obtained information
was in a language other than English, translation software
(Google Chrome web browser, Google Translate, or Babylon
free web-based translation services) or consultation with
native language speakers were utilized for translation to
English. Because this study did not involve the collection, use,
or transmittal of individually identifiable data, Institutional
Review Board (IRB) review or approval was not required. No
formal review protocol exists for this study.
Based on the initial findings, internet research was per-
formed to acquire publically available reports, publica-
tions, and supporting resources to apply inclusion criteria
and identify registries suitable for detailed analysis. Obser-
vational studies similar in content to registries and meet-
ing inclusion criteria were also considered. Inclusion
criteria were registry activity for the 5-year period span-
ning June 2007 to June 2012, data collection for ≥300 pa-
tients, and availability of information on dialysis use and
type. Thus, transplant-only registries were excluded from
this study. We also excluded registries if their data were
duplicated elsewhere, favoring the registry with the most
recent or comprehensive data. An exception to this was
the European Renal Association - European Dialysis and
Transplant Association (ERA-EDTA) registry, which col-
lates data from registries of over 30 countries. This registry
was reported in aggregate; however, participating individ-
ual registries were analyzed separately if they contained
more complete information than the ERA-EDTA itself.
Registries meeting inclusion criteria were further ana-
lyzed to obtain data on a comprehensive list of parameters
as outlined in Table 1. Key variables included registry his-
tory; population; current activity; incidence, prevalence,
and availability of aggregated or individual patient data;
treatment characteristics (dialysis type and modality and
transplant status); and clinical and economic outcomes.
Publically available information rarely provided sufficient
information about the scope of registry data elements
collected or patient-level data availability for external re-
searchers. Therefore, if the publically available information
was insufficient, as part of the data collection process, up
to 3 attempts were made to establish contact with registry
personnel by email. An email template covering the same
basic elements but tailored to each registry type, if needed,
was used. Telephone contact was made if feasible for the
Table 1 Data elements sought
Category Data elements
Basic registry information Region, acronym, full name, website, country, year established, year of latest annual report, address, telephone/fax
numbers, email, Chairperson, Director, history, current status (active or inactive), patient group, inclusion of pediatric data,
geographical reach, use of quality control measures, inclusion of incident and/or prevalent patients, use of special
inclusion sampling, inclusion of transplant and/or dialysis patients
Aggregate data Availability, how to access, who can access, cost to access
Individual patient data Availability, how to access, who can access, cost to access
Data source Sector (public or private), RRT service provider, method of patient recruitment, means by which patients exit registry
Patient characteristics Age, gender, race, ethnicity, body mass index, duration of ESRD, level of education, employment status, insurance
Comorbidities Whether reported, specific comorbidities assessed
Treatment characteristics Modality and submodality, dialysis-product information, dose of dialysis, vascular access method, if RRT initiation was unplanned
or planned, if start date reported, length of time on dialysis, treatment costs, funding source
Outcomes Laboratory results, quality of life (scale/instrument used), peritonitis rate, infection rate, other adverse events reported,
survival data/all-cause mortality rates, renal failure-related mortality rates, any additional outcomes collected
ESRD, end-stage renal disease; RRT, renal replacement therapy
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email attempts (using local language content as appropri-
ate, translated as described above), further contact at-
tempts were not made.
A tailored assessment tool was developed to suit our
purposes, ie, evaluating how renal registries can be used
to steer public policies and improve patient care. The
main focus of the assessment was on the availability of
registry information to the general public and accessibil-
ity of patient-level data to external researchers. Specific
registry features included amenability to collaboration
with outside clinicians, payers, or researchers (academic
or corporate) to enable use of registry data to address a
variety of questions. General data accessibility was deter-
mined through both web-based search results and direct
communications with registry personnel, and assigned to
1 of 3 categories as described below. All registries were
assessed by at least 2 data analysts, with any noted dis-
crepancies discussed and resolved.
Accessibility was defined as good (information including
annual reports, publications, and aggregate data accessible
via website, publicly available materials, or with assistance
from registry staff);moderate (information in local language
only or limited publicly available information including on
website; with additional searches, basic information may be
available in reports or in published research; more informa-
tion may be accessible via third party collaborators); or
limited/unclear (little or no information publicly available).
Patient-level data accessibility was determined in a
similar manner, and categorized as available (to external
researchers directly or through application and review,
may include usage fees); conditionally available (eg, via
third party collaborators); or not available/unclear.
Treatment data were ranked as good if dialysis sub-
modality was available, moderate if modality but notsubmodality was available, and limited if the modality
was not available or unclear.
Outcome data was categorized as good if mortality,
survival and/or hospitalization, or complications data
were available; moderate if mortality/survival or adverse
events were not reported but surrogates such as labora-
tory result data were available; and limited if outcomes
or surrogate data were not reported or unclear.
Results
The initial literature search yielded 1980 references that
included data elements suggestive of renal registry activity
(comprehensive search results are provided in Additional
file 1). Screening titles and abstracts for renal registry
names, combined with manual web searches, yielded 144
registries considered for further review (Figure 1). Subse-
quent application of the inclusion criteria resulted in 53
registries eligible for screening and review, all of which
were contacted by email or telephone. In addition to the
91 registries immediately excluded for not meeting inclu-
sion criteria, 3 registries (Israeli Society of Nephrology and
Hypertension, Madrid Registry of Renal Patients, and Polish
Registry of Renal Replacement Therapy in Children) were
excluded due to insufficient available information, and 2
(Scientific Registry of Transplant Recipients and Japan
Renal Transplantation Registry) were excluded due to lack
of dialysis data, leaving 48 registries for detailed analysis.
A list of available websites, representative publications,
and reports for these 48 analyzed registries is provided in
Additional file 2.
The geographic distribution of the analyzed registries
is shown in Figure 2. The majority were in Europe (23
[47.9%]), followed by the Asia/Pacific region (8 [16.7%])
and North America (7 [14.6%]). We also analyzed 4

















Figure 1 Registry data analysis and reporting process. aA
registry was excluded if it had been defunct for more than 5 years,
had ≤300 participants, did not include data related to dialysis, was
contained in and/or was redundant to another registry that was more
appropriate for analysis. bReviewed databases not reported due to lack
of available information (ie, insufficient data available through public
sources and did not respond to queries for more information) included
Israeli Society of Nephrology and Hypertension (The Official Israeli
Nephrology Site), Madrid Registry of Renal Patients (although it did
provide aggregate data to the Spanish Registry of Renal Patients), and
Polish Registry of Renal Replacement Therapy in Children. The Scientific
Registry of Transplant Recipients and Japan Renal Transplantation Registry
were also excluded for focusing exclusively on transplant patients and
providing no information on dialysis modalities.
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clusion criteria were identified in some Asian countries
with large populations including India, the Philippines,
and Indonesia. Moreover, no registries were identified in
Africa at the time of this evaluation (see Discussion),
although Morocco and Tunisia were included in the
French Language Peritoneal Dialysis Registry.
Details of the 48 analyzed registries are summarized in
Table 2. Overall, there was significant heterogeneity be-
tween organizational structures and histories between regis-
tries. Initiation dates ranged over 45 years (1963 to 2010),
and registry history included de novo establishment as well
as transition from or acquisition of preexisting registries by
newer or larger registries. Few of the 48 analyzed registries
provided information on patient racial origin/ethnicity, edu-
cation, employment, insurance, dialysis access, dialysis start
(planned vs unplanned), complications, quality of life
(QoL), and treatment costs (details not shown).
Among the characteristics assessed for the 48 regis-
tries, the focus was on 4 major areas: public availability
of registry data such as annual reports or aggregate data,
availability of individual patient-level data to outsideresearchers, RRT modality and submodality information,
and details on reported patient outcomes with a focus
on mortality. As shown in Table 2, we categorized these
4 parameters using a low-medium-high (+/++/+++) rat-
ing scheme as described in the Methods.
Overall, 17 registries (35.4%) had good public accessibil-
ity and 22 registries had moderate accessibility (48.5%) to
general information and/or aggregate data. Additional de-
tails about registries considered to have good public acces-
sibility to information are provided in Table 3, with their
regional distributions depicted graphically in a pie chart in
Figure 2. Patient- level data were not accessible to exter-
nal researchers (or access was unclear) for the majority
of registries (25 of 48, [52.1%]). Patient-level data were
available to external researchers either directly or
through application and review (which may include usage
fees) for 13 registries (27.1%), and 10 (20.8%) had condi-
tional data availability. Examples of conditional data avail-
ability include the Korean Renal Registry (available for
academic purposes only), the US Renal Data System
(USRDS; available through a registry coordinating center
or through a third party approved research team and re-
quest), and the Dialysis Outcomes and Practice Patterns
Study (DOPPS; potentially available to corporate spon-
sors). Latin/South America had the highest proportion of
registries with patient-level data accessible to external re-
searchers (3 of 5 [60.0%]), followed by multiregional regis-
tries (2 of 4 [50%]), North America (2 of 7 [28.6%), Europe
(5 of 23 [21.7%]), and Asia (1 of 8 [12.5%]). No patient-
level data were available in the Middle East. We identified
7 registries allowing external access to patient-level data
that reported RRT modality and submodality and had
comprehensive outcomes data. These were Danish Registry
on Regular Dialysis and Transplantation, Finnish Registry
for Kidney Diseases, Scottish Renal Registry, French
Language Peritoneal Dialysis Registry, United Kingdom
Renal Registry, Argentina Society of Nephrology/Central
National Institute Unique Coordinator of Ablation and
Implant, and the Uruguayan Registry of Dialysis.
Treatment data, including general categories PD and
HD, were available from most registries. However, the
number reporting submodalities of PD (continuous am-
bulatory PD [CAPD], automatic PD [APD]); type of HD
(clinic versus home; high-dose HD); or hemofiltration
and hemodiafiltration was more limited. When assessing
RRT data availability, submodality details were identified
for more than half (28 [58.3%]) of all registries, whereas
17 (35.4%) provided modality but not submodality data.
For the remaining 3 registries (6.3%), modality data was
unavailable or unclear. Treatment cost data (not shown)
was identified for only 4 (8.3%) analyzed registries:
USRDS, Thailand Renal Replacement Therapy Registry,
Colombia Healthcare Database, and Spanish Society of






























Figure 2 Geographical distribution of analyzed registries (n = 48).
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of mortality, survival, hospitalization, or complications
data. Registries that provided data on at least 1 of these
outcomes were rated as having the best outcomes data;
whereas, the next tier included registries offering partial
information and/or surrogate outcome data like labora-
tory results. Over half (32 [66.7%]) of the registries pro-
vided mortality, hospital or complications outcomes
data; the largest proportion of which came from Europe
(19 of 23 [82.6%]), followed by Asia-Pacific (6 of 8
[75.0%]), Latin/South America (3 of 5 [60.0%]), North
America (3 of 7 [42.9%]), and none in the Middle East.
The multiregion French Language Peritoneal Dialysis
Registry had good availability of outcomes as well as
treatment data with most centers in France but also
from other French speaking countries in Europe and
North Africa.Discussion
Based on our survey of renal registries, we identified 144
for further evaluation, and analyzed 53 in detail. Subse-
quently, 3 were excluded for not meeting inclusion cri-
teria and 2 more for lack of available information,
resulting in 48 registries analyzed and reported. Most of
the 48 registries provided information on transplantation
and dialysis modality, yet very few provided treatment
cost data or clinical or patient outcomes other than on
mortality. Of the 48 analyzed registries, 17 were deemed
to provide good public access to information such as de-
tailed reports and publications, and 23 were determined
to allow access to individual-level patient data as re-
quired to conduct real-world research. Several of these
registries offered data analysis services through registry
statisticians as part of a contracted research project or
via collaboration with registry researchers.
Table 2 Data summary for reported registries (n = 48)





Australia and New Zealand Dialysis and Transplant Registry (ANZDATA), 1963 +++ ++ +++ +++
Hong Kong Renal Registry (HKRR), 1995 + + +++ +++
Korean Renal Registry, 1985 ++ ++ +++ +++
Malaysian National Renal Registry (NRR), 1993 ++ +++ +++ +++
Shanghai Dialysis Registry, 1996 + + ++ +++
Singapore Renal Registry, 2001 +++ ++ +++ +++
Taiwan Renal Registry Data System (TWRDS), 1987 + + +++ +
Thailand Renal Replacement Therapy Registry (TRT), 1997 ++ + +++ +
Europe (n = 23) Austrian Dialysis and Transplant Registry (OEDTR)*, ≤ 1990 ++ + ++ +++
Belgian Society of Nephrology (Dutch-speaking) (NBVN)*, ≤ 1996 ++ ++ +++ +
Catalan Renal Registry (RMRC)*, 1984 ++ + ++ +++
Danish Registry on Regular Dialysis and Transplantation (DNSL)*, 1990 +++ +++ +++ +++
Dutch Renal Registry (RENINE), 1986 ++ + ++ +++
European Renal Association - European Dialysis and Transplant Association
(ERA-EDTA), 1963
+++ ++ +++ +++
Finnish Registry for Kidney Diseases*, 1964 +++ +++ +++ +++
French Renal Epidemiology and Information Network (REIN), 2002 ++ + +++ +++
Greek Registry (Hellenic Society of Nephrology)*, 2000 + + + +
Groupement des Nephrologues Francophones de Belgique (GNFB), 1995 ++ + ++ +++
Italian Dialysis and Transplant Registry (RIDT)*, 1996 +++ + ++ +++
Norwegian Renal Registry*, 1994 ++ +++ ++ +++
Peritoneal Dialysis Board Registry (GSDP), ≤ 2001 ++ + +++ +++
Portuguese Society of Nephrology*, 1997 ++ + ++ +++
Romanian Renal Registry (RRR)*, 1993 + ++ ++ +
Russian Registry*, 1998 ++ + +++ +++
Scottish Renal Registry (SRR)*, 1991 +++ +++ +++ +++
Spanish Society of Nephrology Register (Peritoneal Dialysis Registry)
(SEN), 1997
++ + ++ ++
Spanish Society of Nephrology Register (Records of Renal Patients
[GRER]), 1997
++ + +++ +++
Swedish Renal Registry (SNR/SRR)*, 2007 ++ ++ ++ +++
Turkish National Registry (TSNRR)*, 1990 ++ + +++ +++
United Kingdom Renal Registry (UKRR)*, 1997 +++ +++ +++ +++
Valencian Renal Registry*, 1992 +++ ++ +++ +++
Latin/South
America (n = 5)
Sociedad Argentina de Nefrologia (SAN)/Instituto Nacional Central
Unico Coordinator de Ablación e Implante (INCUCAI); 2004
+++ +++ +++ +++
Brazilian Registry of Dialysis (RBD/SBN), 1998 + + ++ +++
Colombia Healthcare Database, ≤ 2008 +++ +++ ++ +
Latin American Dialysis and Transplantation Registry (SLANH/RLDT), 1991 ++ + ++ +
Uruguayan Registry of Dialysis, 1981 +++ +++ +++ +++
Middle East
(n = 1)
United Arab Emirates Renal Diseases Registry, 1980 + + + +
North America
(n = 7)
British Columbia Renal Database - Patient Records and Outcome Man-
agement Information System (PROMIS), 2003
+ +++ ++ +
Canadian Organ Replacement Register (CORR), 1994 +++ +++ +++ ++
Canadian Pediatric End-Stage Renal Disease Database, ≤ 2010 ++ + + +
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Table 2 Data summary for reported registries (n = 48) (Continued)
Database of the Renal Research Institute (MONDO), 2000 ++ + ++ +
North American Pediatric Renal Trials and Collaborative Studies
(NAPRTCS), 1987 transplant only, HD/PD as of 1992
+++ + +++ +++
The Renal Disease Registry (TRDR/ORN), 1981 ++ + +++ +++
US Renal Data System (USRDS), 1988 +++ ++ +++ +++
Multiregional
(n = 4)
Dialysis Outcomes and Practice Patterns Study (DOPPS), 1996 +++ ++ ++ ++
French Language Peritoneal Dialysis Registry (RDPLF), ≤ 1995 +++ +++ +++ +++
International Pediatric Peritoneal Dialysis Network Registry (IPPN), 2007 + +++ +++ +
International Quotidian Dialysis Registry (IQDR), 2003 ++ + +++ +
*Registry contributes to ERA-EDTA.
Full references to online registry resources are provided in Additional file 2.
Accessibility: +++(Good): Information including annual reports, publications, and aggregate data accessible via website, publicly available records, or with
assistance from registry staff; ++(Moderate): Information in local language only or limited publicly available information including on website; with additional
searches, basic information may be available in reports or in published research; more information may be accessible via third party collaborators (eg, registry
researchers or local academics); +(Limited/unclear): very limited information available publicly or unclear.
Patient-level data: +++Available to external researchers directly or through application and review, may include usage fee; ++Conditional access, eg, via third
party collaborators; +Not available to external researchers or access process unclear.
Treatment: +++ Submodality available; ++Modality available but not submodality; +Modality not available or availability unclear.
Outcome data: +++ Mortality/survival and/or hospitalization/complications data available; ++ Mortality/survival or hospitalization/complications not reported;
surrogates such as laboratory result data reported; +No reported outcomes or surrogate data or availability unclear.
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complete clinical, humanistic, and economic information
on patients are essential to help monitor and improve
patient outcomes. Health care systems should have a
vested interest in supporting registry activity, particularly
in acquiring, maintaining, and analyzing the data. High-
quality registries provide valuable information that can
impact health care procedures, policy, and ultimately,
population health. A number of therapeutic areas pro-
vide powerful examples of how registry data can posi-
tively affect patient care. For example, the European
Network of Cancer Registries publishes fact sheets and
treatment recommendations, provides training courses,
and holds international conferences to present the latest
data and recommendations to improve patient assessment
and care [10]. In the US, the National Cardiovascular
Disease Registry provides evidence-based quality improve-
ment solutions for HCPs and guidance on facility-based
issues like accreditations, cost control, reimbursements,
and securing and retaining high-level clinicians [11]. Simi-
lar programs could be of significant benefit for ESRD pa-
tients, some of which have already begun. For example,
cost data ascertained through the USRDS helped drive a
recent shift in health care policy with the End-Stage Renal
Disease Prospective Payment System, designed to better
manage costs for ESRD treatment [12]. Data from the
ESRD Networks in the United States (www.esrdncc.org)
support the Fistula First Breakthrough Initiative, intro-
duced to advance arteriovenous fistula placement and
reduce central venous catheter use to improve patient
survival and QoL by providing a number of incentives for
both patients and health care providers (see http://www.
fistulafirst.org). The peritoneal dialysis first initiative by
the Universal Health Coverage Scheme (UCS) in Thailand[13] and the call to action by nephrologists from Australia
and New Zealand use ESRD registry data to address ob-
served low survival rates with PD [14]. Finally, the Latin
American Dialysis and Renal Transplant Registry along
with the Latin American Society of Nephrology and
Hypertension have supported a sustained effort within the
entire Latin American nephrology community by hosting
seminars for the creation and/or improvement renal regis-
tries throughout Latin America [15,16].
We identified a number of gaps in renal registry cover-
age, revealing that, despite large ESRD patient populations
and an established framework for data collection in many
countries, opportunities for tracking patient care are being
missed. First, although many renal registries have been
established around the world, less than half that met our
analysis criteria provided information accessible to the
general public, and few had suitable patient-level data
availability and access needed to generate evidence to sup-
port improved patient care. Data on the burden of dialysis
on patients and caregivers and on societal and payer costs
of care were also limited. Second, few registries were iden-
tified in areas with emerging economies; the majority
being based in high-income countries, creating geographic
gaps in coverage. In much of the Asia-Pacific region, the
Middle East, and Africa, registries were either absent en-
tirely or had limited data or poor accessibility for outside
research. Additionally, some of the world’s most populous
health care systems like China, Russia, and India currently
have limited (eg, limited to 1 city like Moscow or Shanghai)
or inadequate registries. Of particular note is India, which
has an age-adjusted incidence of ESRD of 232 per mil-
lion population [17]. Although some ESRD patients are
captured in the India chronic kidney disease registry,
[18] there is no specific registry for ESRD.
Table 3 Renal replacement modality for registries with good accessibility to general information1 (n = 17)




Renal replacement modality reported2
HD PD Transplant
Australia and New Zealand Dialysis and
Transplant Registry
Australia, New Zealand 1963 Yes3 Home, Clinic CAPD, APD Yes
Canadian Organ Replacement Register Canada 1994 Yes3 Home, Clinic CAPD, APD Yes
Colombia Healthcare Database Colombia 20084 Yes Unspecified Unspecified Yes
Danish Registry on Regular Dialysis and
Transplantation
Denmark 1990 Yes3 Home, Clinic APD Yes




Japan, Italy, New Zealand,
Spain, Sweden, UK, USA
1996 Conditional5 Clinic Unspecified No
European Renal Association - European Dialysis
and Transplant Association (ERA-EDTA),
Europe 1963 Conditional5 Home, Clinic6 CAPD, APD Yes
Finnish Registry for Kidney Diseases Finland 1964 Yes3 Home, Clinic CAPD, APD Yes





≤1995 Yes3 Unspecified CAPD, APD Yes
Italian Dialysis and Transplant Registry Italy 1996 No Clinic CAPD, APD Yes









Unclear Clinic CAPD/APD/IPD Yes
Scottish Renal Registry Scotland 1991 Yes3 Home, Clinic CAPD, APD Yes
Singapore Renal Registry Singapore 2001 Yes3 Clinic CAPD, APD Yes
Sociedad Argentina de Nefrologia (SAN)/
Instituto Nacional Central Unico Coordinator
de Ablación e Implante (INCUCAI); 2004
Argentina 2004 Yes Unspecified CAPD/APD Yes
United Kingdom Renal Registry UK 1997 Yes3 Home, Clinic CAPD, APD Yes
Uruguayan Registry of Dialysis Uruguay 1981 Yes Clinic CAPD, APD Yes
US Renal Data System USA 1988 Conditional5 Home, Clinic CAPD, APD Yes
Valencian Renal Registry Italy 1992 Unclear Clinic CAPD, APD Yes
APD, automated peritoneal dialysis; CAPD, continuous ambulatory peritoneal dialysis; HD, hemodialysis; PD, peritoneal dialysis.
1Data derived from publicly accessible information and may not be comprehensive or reflect full range of collected information.
2Hemofilration use not available except for Finnish Registry for Kidney Diseases and Italy (12 of 20 regions as per ERA-EDTA). Dialysis product information not
available for any registry listed.
3Application/inquiry process required.
4Year of are earliest publicly available data. Year of registry establishment unclear.
5Access conditional via registry staff led research or collaborative partner.
6Large majority of data are in-center/clinic dialysis.
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quality of data collected and in how modalities were
reported. For example, some registries reported high-level
information on HD and PD submodalities, but did not
provide details on associated outcomes (eg, the USRDS re-
ported the percentage distribution of CAPD vs. APD, but
not outcomes from these). Limited data are available in
registries to compare the use of, or outcomes in, patients
receiving hemodialysis vs. hemodiafiltration in Europe
despite its wide availability across that region. Thus, the
performance of different dialysis methods in a real-world
clinical setting is poorly understood due to limitations in
existing registry data. This is a particular concern consid-
ering that registries are generally not organized or fundedto integrate new data elements [1], and thus information
on submodalities may be missed as dialysis therapies
evolve. Current treatment data need to be incorporated
into registries to address this gap in dialysis treatment
information.
Finally, we also encountered a general difficulty in
accessing detailed registry data; both aggregated data for
the general public, and patient-level data for external
research. We concluded that research using many of the
identified renal registries with high-quality information
would be restricted by both limited data collection and
dissemination as well as access to external researchers.
Even for registries that might be receptive to collabor-
ation, registry personnel may lack time or resources to
Liu et al. BMC Nephrology  (2015) 16:31 Page 9 of 10conduct and publish studies, resulting in a backlog of in-
formation that is not disseminated. Although there ini-
tially appeared to be a large number (144) of renal
registries globally, only a small minority had comprehensive
patient-level data readily accessible for external research,
and these tended to be in high-income countries. These
restrictions on registry data accessibility limit opportunities
for real-world research of treatment patterns and associated
outcomes, potentially missing opportunities to improve
patient care.
This study has several limitations. First, the analysis
was completed as of June 2012, and thus some newer
registries like the recently established South African
Renal Registry (first annual report published in 2014)
were not included. It is also possible that the registries
we examined here added or made available new informa-
tion since our analysis was completed. Second, if a regis-
try was operating with no public-facing information like
a website, periodic reports, or literature publications, it
could have gone undetected. Finally, it should be noted
that the ranking system (eg, as shown in Table 2) was in-
herently subjective, based on best information available
at the time and the researchers’ interpretation of this
information.
Based on the study findings, a number of recommenda-
tions emerged. Gaps in registry coverage, data collection and
completeness of case ascertainment, and accessibility present
an opportunity for more productive collaborations to collect
relevant data, implement quality and standardization proce-
dures, and provide broad access to comprehensive aggregate
information and anonymized patient-level data to facilitate
the advancement of patient care. Communication with local
governments and health authorities can be initiated to begin
to address data gaps identified in this analysis to improve
data quality and accessibility. New data elements and key
patient information (eg, detailed patient information; dia-
lysis access, new modalities, and initiation dates; QoL; and
costs) could be incorporated into existing registries. Add-
itionally, specific mechanisms to report and improve data
quality, resources to maintain and update registries, and
increased accessibility are needed. For example, inroads to
existing, seemingly difficult-to-access renal registries could
be developed to expand opportunities for more thorough
data analysis and outcomes research, thus leveraging the
existing registry infrastructure while building collaboration.
Through multistakeholder collaboration, opportunities
could be pursued to develop or expand renal registries in
large but poorly represented countries such as India,
China, and the Russian Federation. These partnerships
could help address the human resource and financial issues
inherent in maintaining a high-quality registry. Addition-
ally, established registries or societies like the International
Society of Nephrology could potentially assist with the
formation of new registries in less developed countries byproviding assistance with process and protocol develop-
ment, information technology expertise, and infrastructure
required to initiate patient registries. Finally, global
guidelines for uniform and centralized data collection
and quality assurance across all geographic areas could
be proposed. Current examples of this type of initiative
include the recently established EURODOPPS (a part-
nership between the ERA-EDTA and Dialysis Outcomes
and Practice Patterns) [19,20], the Registry of Patient
Registries by the US Agency for Healthcare Research and
Quality; and the ERA-EDTA/SLANH Registries Fellow-
ships [21]. These programs help expand knowledge on the
epidemiology of ESRD and treatment approaches by
leveraging strengths and pooling the resources of multiple
initiatives. This can help address scientific and policy
questions, facilitate research, compare and pool results
between registries, and use the strengths contained in
multiple registries to generate new insights into treat-
ments for ESRD patients.
Conclusions
Existing registries can provide valuable information about
ESRD patients and inform or help monitor the implemen-
tation of policy for renal care, but registries vary in terms
of types of data collected, data quality, and accessibility.
Insufficient information is available on the range of new
dialysis modalities, as well as on socioeconomic factors,
comorbidities, QoL and clinical outcomes, and costs of
care. Even when these data are collected, dissemination to
the public may be poor, and data accessibility is often diffi-
cult for external researchers. Limited data are available
from emerging economies, resulting in information gaps
about health care and outcomes for large populations of
ESRD patients. Effective collaborations or partnerships
with existing registries or societies could help to develop
renal registries where they currently do not exist, or en-
hance data collection and dissemination for currently
existing registries.
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